Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04783545 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of VLX-1005 in Healthy Subjects
A Phase 1 study, sponsored by Veralox Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT04783545 is a Phase 1 study that has completed, run by Veralox Therapeutics. The registered enrollment target is 96 participants.
The verdict
NCT04783545, a Phase 1 study, has completed, sponsored by Veralox Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
The principal objective of this study is to describe the safety of and tolerability to single and multiple doses of VLX-1005 in healthy subjects following intravenous (IV) administration. Other exploratory objectives are: To evaluate the pharmacokinetics and pharmacodynamics of VLX-1005 following IV administration.
Interventions
- DRUG Placebo
- DRUG VLX-1005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2021-03-24 |
| Est. Completion | 2022-01-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04783545
The ClinicalTrials.gov registry entry for NCT04783545 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veralox Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04783545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04783545 about?
NCT04783545 is a clinical study titled "Phase I Study of VLX-1005 in Healthy Subjects". The principal objective of this study is to describe the safety of and tolerability to single and multiple doses of VLX-1005 in healthy subjects following intravenous (IV) administration. Other exploratory objectives are: To evaluate the pharmacokinetics and pharmacodynamics of VLX-1005 following ...
What is the current status of trial NCT04783545?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2021-03-24. Estimated completion is 2022-01-11.
What interventions are being tested in trial NCT04783545?
The interventions under investigation include: Placebo (DRUG), VLX-1005 (DRUG).
Who is sponsoring clinical trial NCT04783545?
This trial is sponsored by Veralox Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.